#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anti-myelin-associated glycoprotein antibodies positive Langerhans cell sarcoma Oesophageal adenocarcinoma stage II Acute lymphocytic leukaemia Oropharyngeal cancer recurrent Medullary thyroid cancer Neonatal alloimmune thrombocytopenia Bronchopulmonary dysplasia Acute graft versus host disease in liver Systemic candida Medulloblastoma recurrent Thalassaemia Juvenile idiopathic arthritis Erdheim-Chester disease Obliterative bronchiolitis More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis II – Basic Information Waldenstrom’s macroglobulinaemia recurrent – Treatment MELAS syndrome – Diagnostics Idiopathic inflammatory myopathy – Trials in Disease Leiomyosarcoma metastatic – Treatment Hepatic angiosarcoma – Basic Information Marginal zone lymphoma refractory – Trials in Disease Haemophilia B without inhibitors – Treatment Langerhans cell sarcoma – Diagnostics Alveolar rhabdomyosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Galunisertib AZD3632 Poractant Alfa Tolvaptan SODIUM HYDROXIDE Cefuroxime Rbl015.2 Tyrosine Lonvoguran Hyoscine Brinzolamide Timbetasin Acetate VANADIUM OXIDE SULFATE Ivabradine Xanthum Gum Naproxen Cefaclor Selgantolimod ANOC-001 Nanatinostat More therapies…

    Learn about Your Condition

    Carotid artery stenosis Bacterial vaginosis Inclusion body myositis Mucosal inflammation Hyperoxaluria Facial paresis Psychotic disorder Sleep disorder Fracture infection Sjogren's syndrome Barrett's oesophagus Multiple sclerosis relapse Scoliosis Metachromatic leukodystrophy Spinal cord injury cervical More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rath Gyorgy Utca 7-9, Kerulet, Budapest, 1122, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Gastrointestinal cancer metastatic
    • Embolism venous
    Investigated Drugs:
    • Abelacimab
    • Dalteparin Sodium
    Austria Czechia France Germany Hungary Ireland +6

  • Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Atezolizumab
    • Regorafenib
    Belgium France Germany Hungary Poland Portugal +1

  • Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Relacorilant
    • Paclitaxel Albumin-Bound
    Belgium France Hungary Italy Poland Spain

  • Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Capivasertib
    • Docetaxel
    Belgium Czechia France Greece Hungary The Netherlands +2

  • Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Talazoparib
    • Avelumab
    • Axitinib
    Belgium Denmark France Hungary Italy Poland +1

  • Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Epcoritamab
    • Gemcitabine
    • Lenalidomide
    Belgium Bulgaria Croatia Czechia France Greece +5

  • Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Olaparib
    • Durvalumab
    • Infliximab
    Belgium Estonia Germany Greece Hungary Lithuania +2

  • Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal cancer metastatic
    • Oesophageal carcinoma
    • Gastric cancer
    Investigated Drugs:
    • Domvanalimab
    • Zimberelimab
    • Calcium Folinate
    France Greece Hungary Italy Lithuania Poland +3

  • Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Paclitaxel
    • Paclitaxel Albumin-Bound
    Austria Belgium Denmark France Germany Hungary +6

  • Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Camizestrant
    • Fulvestrant
    Belgium France Hungary Italy Poland Portugal +1
Previous Page
1 … 7 8 9 10 11 … 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!